Ventyx Biosciences, Inc. (VTYX) Tops Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Ventyx Biosciences, Inc. (VTYX) Tops Q2 EPS by 8c

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

August 7, 2025 4:05 PM EDT

Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinsons disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash, cash equivalents and marketable securities balance of $209.0M as of
June 30, 2025 expected to fund planned operations into at least H2 2026

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ventyx... More